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Transfusion-transmitted virus (TTV) is an unenveloped circular single-stranded DNA virus with a 
diameter of 30 to 32 nm that was first described in 1997 in Japan. TTV was detected in various 
populations without proven pathology, including blood donors and in patients with chronic hepatitis B 
virus (HBV) and hepatitis C virus (HCV). The aim of this study was to determine the prevalence of TTV 
DNA in patients with chronic hepatitis B and C in southwest Iran. Viral TTV-DNA was studied in 442 
samples (202 with HBV, 138 with HCV and 102 controls) collected from southwest of Iran. All the 
extracted serum DNA was amplified by TTV ORF1 gene specific primers using the semi nested 
polymerase chain reaction (PCR) technique. TTV DNA was detected in the serum of 8.9 and 10.8% 
patients with chronic hepatitis B and C, respectively. The prevalence of TTV-DNA in the serum of the 
102 controls was 2.9%. The results showed significant relationship of TTV with HBV and HCV in 
patients from T test examination (P < 0.01). The prevalence of TTV-DNA in Iranian hepatitis B and C 
patients was rather high when compared with those of other countries. To control and prevent the 
distribution of TT-virus, examination of the blood and blood products seems necessary.  
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Transfusion-transmitted virus (TTV) was isolated from the 
serum of a Japanese patient with fulminant hepatitis and 
chronic liver disease of unknown etiology (Hsieh et al., 
1999). TTV, like parvovirus, does not have an envelope. 
Its genome consists of a single-stranded, linear DNA 
molecule of about 3.818 to 3.853 nucleotides in length 
(Okamoto et al., 1998). TTV is a member of the 
Circoviridae family and Anellovirus genus, and has not 
been cultured in vitro and its pathogenic potential is still 
not clear (Abe et al., 1999). TTV DNA has been detected 
in the blood of newborns, cord blood, semen, saliva, 
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Okamoto et al., 1998; Tanaka et al., 2001). The TTV 
chronically infects healthy individuals of all ages in 
different populations of the world (Alfaresi et al., 2006). 
TTV is transmitted parenterally and typically by trans-
fusion of blood and blood products, and is shed via the 
bile into the feces of infected individuals for possible 
fecal-oral transmission (Muljono et al., 2001). TTV is 
found in the plasma and peripheral blood mononuclear 
cells, different body fluids and secretions such as stools, 
saliva, semen, vaginal fluid, breast milk and tears (Inami 
et al., 2000; Kheradpezhouh et al., 2007). TTV also has 
been found in other organs including kidneys, prostate, 
mammary glands, brain and bone marrow cells (BMCs) 
(Irshad et al., 2006; Wagner et al., 2006). 
Hepatitis B and C viruses (HBV and HCV) cause 
transient and chronic infections of the liver, which may 
progress to cirrhosis and eventually to hepatocellular 
carcinoma (HCC). Coinfection of TTV and HBV or TTV 
and HCV is common, because these viruses share the 
same   transmission   routes   such  as  blood  transfusion  





(Garcia et al., 2003; Polz et al., 2008). Prevalence of TTV 
ranges from 1.9 to 37%, respectively, in the general 
population or in healthy voluntary blood donors in diffe-
rent countries (Huang et al., 2000). Coinfection of HBV 
infected patients with TTV differs from 8 to 35%. The 
Data of HCV and TTV coinfection are similar to the earlier 
which is within the range of 8 and 42% (Schreter et al., 
2004). According to the report in 2007, the seropre-
valence of TTV was 9.3% in Iranian hemodialysis patients 
(Kheradpezhouh et al., 2007). 
TTV was originally found in humans; however, recent 
studies showed that TTV can also be identified in serum 
specimens obtained from domesticated farm animals and 
from non-human primates. One study demonstrated 
frequent TTV infection of domestic animals such as cows, 
pigs, sheep and chickens (Simmonds et al., 1999). How-
ever, it is unknown how these species acquire TTV 
infection. There are some reports showing high preva-
lence of TTV infection in captured chimpanzees and 
crabs eating macaques (Inami et al., 2000). These 
findings suggest that TTV is widespread among wild 
chimpanzees living in West Africa (Irshad et al., 2006). 
Many studies have shown that TTV is not the causative 
agent of chronic liver disease of unknown etiology and 
neither does it affect the degree of liver damage when 
present as a coinfection with HBV or HCV (Irshad et al., 
2006). Yet, no significant difference between TTV 
infected and non-infected patients were found for the 
demographic data, assumed source of infection, 
biochemical abnormalities or severity of liver histology 
(Tangkijvanich et al., 1999). Thus, regarding etiology and 
progression towards serious chronic liver disease, its 
contribution seems to be minor if not all together non-
existent. Concerning antiviral therapy, there are no data 
or treatment for patients who are infected with TTV alone 
since the role of TTV as a cause of chronic hepatitis is 
yet to be determined (Irshad et al., 2006). 
The aim of this study was to determine the prevalence 
of TTV in patients with chronic HBV and HCV in the 
southwest of Iran via the tracing of the ORF1 gene of this 
virus by using a semi nested polymerase chain reaction 
(PCR) method.   
 
 




After agreement with the private and governmental clinical patho-
logic laboratories and clinical centers in southwest of Iran, 340 
serum samples were collected from the patients with HBV and HCV 
(202 and 138 HBV DNA and HCV RNA positive, respectively). 
Then, the samples of 102 controls (without hepatitis B or C) with the 
permission of the patients (during 2010) were then transferred to 
the Biotechnology Research Center in ice and stored at -70°C. 
Population study consisted of 102 controls without hepatitis B or 
C (55 men and 47 women; median age: 43.12, range: 25 to 68 
years) and 340 patients (189 men and 151 women; median age: 
47.66 years, range: 24 to 66 years) with chronic HBV or HCV. 




Nucleic acid extraction 
 
DNA was extracted by DNA extraction kit (QIAGEN Ltd., Crawley, 
UK) according to the manufacturer's procedure. The yield of DNA 
was quantified after electrophoresis in 1% agarose gel containing 
0.5 g/ml of ethidium bromide.  
 
 
Determination of TTV-DNA by semi nested PCR 
 
TTV DNA was determined by semi nested PCR with the use of 3 
primers described by Okamoto et al. (2001) for ORF1 gene 
(accession number: AF151683). The three primers were a forward 
primer for ORF1 gene which was TTV-F: 5´- ACAGACAGAGGA 
GAAGGCAACATG -3´, reverse primer for ORF1 gene which was 
TTV-R: 5´- CTGGCATTTTACCATTTCCAAAGTT -3´ and another 
forward primer for the gene was TTV-FF: 5´- GGCAACATGTTATG 





PCR was performed in a 50 l total volume containing 1 g of 
template DNA, 1 M of each primers, 2 mM Mgcl2, 200 M dNTP, 5 
l of 10X PCR buffer and 1 unit of Taq DNA polymerase (Roche 
applied science). The following conditions of PCR were used for 
gene amplification for the first round: initial denaturation at 95°C for 
5 min, followed by 30 cycles of denaturation at 94°C for 1 min, 
annealing at 58°C for 1 min and extension at 72°C for 1 min. The 
program was followed by a final extension at 72°C for 6 min. 2 l 
from the first round amplicon was used as a template for the 
second round PCR. The second round PCR was performed with 
TTV-FF and TTV-R oligonucleotide primers for 25 cycles with the 
same condition. The PCR product was analyzed by electrophoresis 
in 1% agarose gel in 1X TBE buffer and was visualized by ethidium 





The analysis of PCR products of ORF1 gene of TTV on 
agarose gel revealed a 271 bp fragment (Figure 1). In 
this study, all the collected samples were examined for 
the presence of TTV DNA. For further characterization, 
clinical background including mean age, sex and trans-
fusion history of TTV-PCR positive and negative patients 
were evaluated.  
The prevalence of TTV in the controls (without hepatitis 
B or C) and patients with chronic HBV and HCV was 2.9, 
8.9 and 10.8%, respectively, and these results showed 
the significant relationship between TTV and the patients 
that had chronic HBV and HCV with 99% confidence 
level by T test (P < 0.01). Table 1 shows the prevalence 





TTV was first reported in Japan in 1997 by Nishizawa in 
patients with fulminant hepatitis and chronic liver disease 
of unknown etiology (Irshad et al., 2006). The association 
between TTV infection and hepatitis is controversial 
(Mushahwar, 2000; Okamoto et al., 2000). This virus was  
   








Figure 1. Identification of TT virus by semi nested PCR amplification of the ORF1 
gene. Lanes 1 and 2 are positive samples of TTV, lanes 3 and 4 are negative 
samples, lanes 5 and 6 are negative and positive controls, respectively. M, 100 bp 




Table 1. Prevalence of TTV-DNA in the serum samples of 340 hepatitis patients and 102 
controls (without hepatitis B or C). 
 
Sample Number Positive (%) Negative (%) 
HBV-positive 202 18 (8.9) 184 (91.1) 
HCV-positive 138 15 (10.8) 123 (89.2) 
Controls (without hepatitis B or C) 102 3 (2.9) 99 (97.1) 




initially identified in a large number of patients with acute 
and chronic hepatitis patients in most countries (Irshad et 
al., 2006; Zandieh et al., 2005). Concomitant infection 
with TTV and either HBV or HCV is common. However, 
the effect of TTV infection in patients with chronic HBV or 
HCV infection is unknown (Arankalle et al., 2007).  
According to the result of this study, the prevalence of 
TTV in patients with chronic HBV and HCV in the south-
west of Iran was 8.9 and 10.8%, respectively. TTV-DNA 
levels in the liver tissue were equal to or 10 to 100 times 
higher than those in the serum, suggesting that this virus 
is replicated in the liver (Irshad et al., 2006). The 
prevalence of TTV infection caused by blood transfusion 
also differs depending on the country or area. Using the 
PCR, epidemiological studies have indicated a worldwide 
distribution of this virus, with prevalence surveys in the 
general population of 12 to 19% in Japan (Okamoto et 
al., 1998; Nagano et al., 1999), 36% in Thailand (Tanaka 
et al., 1998), 2 to 10% in European countries (Simmonds 
et al., 1998; Naoumov et al., 1998) and 1% in the USA 
(Irshad et al., 2006). The prevalence of TTV in Iranian 
patients with chronic HBV or HCV was the same with the 
prevalence of this virus in the European countries and 
was different from those of Japan and Thailand. 
The prevalence of TTV DNA in the western India varied 
from 6.7% (5 of 75) in chronic hepatitis patients, 24.4% 
(10 of 41) in hemophiliacs to 7.4% (4 of 54) in voluntary 
blood donors and this result was the same with the 
prevalence in this study (Arankalle et al., 20007). The 
prevalence of TTV-DNA in thalassemic patients and 
blood donors in Iran was 57.2 and 20%, respectively 
(Zandieh et al., 2005). 
Recent studies suggested that TTV infection is a 
relatively common virus infection throughout the world in 
different places and different racial groups (Nishizawa et 
al., 1997; Okamoto et al., 1998). According to this finding, 
TTV is highly associated with HBV and HCV infections 
and the region of this study is at risk for this virus. 
Since TTV was discovered a few years ago, many 
studies have been done to assess whether it causes liver  





disease; however, there is still a poor understanding of its 
molecular properties and pathogenic potential. So, the 
results of this research confirmed the results of previous 
studies. It was shown that TTV infection is acquired in 
many patients with chronic HCV and HBV in Iran. On the 
other hand, many researches have shown that the pre-
valence of TTV DNA was higher in patients that had 
received several blood transfusions or blood products. 
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